文献速递产科母胎医学

硫酸镁与高危队列中缺氧缺血性脑病风险

Magnesium sulfate and risk of hypoxic-ischemic encephalopathy in a high-risk cohort.
PubMed 文献 · Am J Obstet Gynecol · 2024-04-03

基于2012至2018年加州围产期质量护理协作组登记的前瞻性活产队列(≥36周,44,314例),妊娠期高血压疾病与缺氧缺血性脑病相关(aOR 1.26)。在妊娠期高血压疾病患者中,产前硫酸镁与缺氧缺血性脑病风险降低相关(aOR 0.71),与中/重度缺氧缺血性脑病风险降低相关(aOR 0.63)。观察性研究不能证明因果关系。

要点

  • 妊娠期高血压疾病与任何严重程度及中/重度新生儿缺氧缺血性脑病均相关(aOR均为1.26)。
  • 妊娠期高血压疾病患者接受产前硫酸镁者,缺氧缺血性脑病风险降低29%(aOR 0.71)。
  • 该人群中硫酸镁与中/重度缺氧缺血性脑病风险降低37%相关(aOR 0.63)。

核心结论

  • 妊娠期高血压疾病与缺氧缺血性脑病及中/重度缺氧缺血性脑病相关。
  • 在妊娠期高血压疾病患者中,产前硫酸镁与新生儿缺氧缺血性脑病及中/重度缺氧缺血性脑病风险显著降低相关。
  • 该观察性研究结果不能证明因果关系,旨在为未来硫酸镁用于足月婴儿的临床试验提供假设。

研究设计与样本

  • 分析2012年至2018年加州围产期质量护理协作组登记中≥36周活产的前瞻性队列,并与加州卫生保健可及性与信息部文件链接。
  • 纳入44,314例独一无二的婴儿。
  • 采用Cochran-Armitage检验评估妊娠期高血压疾病、脑病诊断和硫酸镁使用趋势,并构建分层logistic回归模型。

主要发现

  • 缺氧缺血性脑病诊断、母体妊娠期高血压疾病及硫酸镁使用随时间增加。
  • 与仅患妊娠期高血压疾病者相比,接受硫酸镁治疗的妊娠期高血压疾病患者代表高危人群,更可能公共保险、36至38周分娩、小于胎龄、Apgar评分较低、分娩时需更高级别复苏、胎膜早破延长、早产和胎儿窘迫及手术分娩(所有P<.002)。
  • 妊娠期高血压疾病与缺氧缺血性脑病相关(aOR 1.26 [95%CI 1.13-1.40];P<.001),与中/重度缺氧缺血性脑病相关(aOR 1.26 [95%CI 1.11-1.42];P<.001)。
  • 妊娠期高血压疾病患者中,硫酸镁治疗与新生儿缺氧缺血性脑病风险降低29%相关(aOR 0.71 [95%CI 0.52-0.97];P=.03),与中/重度缺氧缺血性脑病风险降低37%相关(aOR 0.63 [95%CI 0.42-0.94];P=.03)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 该观察性研究结果不能证明因果关系。
  • 研究结果旨在为未来硫酸镁用于足月婴儿的临床试验提供假设。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypoxic-ischemic encephalopathy contributes to morbidity and mortality among neonates ≥36 weeks of gestation. Evidence of preventative antenatal treatment is limited. Magnesium sulfate has neuroprotective properties among preterm fetuses. Hypertensive disorders of pregnancy are a risk factor for hypoxic-ischemic encephalopathy, and magnesium sulfate is recommended for maternal seizure prophylaxis among patients with preeclampsia with severe features. OBJECTIVE: (1) Determine trends in the incidence of hypertensive disorders of pregnancy, antenatal magnesium sulfate, and hypoxic-ischemic encephalopathy; (2) evaluate the association between hypertensive disorders of pregnancy and hypoxic-ischemic encephalopathy; and (3) evaluate if, among patients with hypertensive disorders of pregnancy, the odds of hypoxic-ischemic encephalopathy is mitigated by receipt of antenatal magnesium sulfate. STUDY DESIGN: We analyzed a prospective cohort of live births ≥36 weeks of gestation between 2012 and 2018 within the California Perinatal Quality Care Collaborative registry, linked with the California Department of Health Care Access and Information files. We used Cochran-Armitage tests to assess trends in hypertensive disorders, encephalopathy diagnoses, and magnesium sulfate utilization and compared demographic factors between patients with or without hypertensive disorders of pregnancy or treatment with magnesium sulfate. Hierarchical logistic regression models were built to explore if hypertensive disorders of pregnancy were associated with any severity and moderate/severe hypoxic-ischemic encephalopathy. Separate hierarchical logistic regression models were built among those with hypertensive disorders of pregnancy to evaluate the association of magnesium sulfate with hypoxic-ischemic encephalopathy. RESULTS: Among 44,314 unique infants, the diagnosis of hypoxic-ischemic encephalopathy, maternal hypertensive disorders of pregnancy, and the use of magnesium sulfate increased over time. Compared with patients with hypertensive disorders of pregnancy alone, patients with hypertensive disorders treated with magnesium sulfate represented a high-risk population. They were more likely to be publicly insured, born between 36 and 38 weeks of gestation, be small for gestational age, have lower Apgar scores, require a higher level of resuscitation at delivery, have prolonged rupture of membranes, experience preterm labor and fetal distress, and undergo operative delivery (all P<.002). Hypertensive disorders of pregnancy were associated with hypoxic-ischemic encephalopathy (adjusted odds ratio, 1.26 [95% confidence interval, 1.13-1.40]; P<.001) and specifically moderate/severe hypoxic-ischemic encephalopathy (adjusted odds ratio, 1.26 [95% confidence interval, 1.11-1.42]; P<.001). Among patients with hypertensive disorders of pregnancy, treatment with magnesium sulfate was associated with 29% reduction in the odds of neonatal hypoxic-ischemic encephalopathy (adjusted odds ratio, 0.71 [95% confidence interval, 0.52-0.97]; P=.03) and a 37% reduction in the odds of moderate/severe neonatal hypoxic-ischemic encephalopathy (adjusted odds ratio, 0.63 [95% confidence interval, 0.42-0.94]; P=.03). CONCLUSION: Hypertensive disorders of pregnancy are associated with hypoxic-ischemic encephalopathy and, specifically, moderate/severe disease. Among people with hypertensive disorders, receipt of antenatal magnesium sulfate is associated with a significant reduction in the odds of hypoxic-ischemic encephalopathy and moderate/severe disease in a neonatal cohort admitted to neonatal intensive care unit at ≥36 weeks of gestation. The findings of this observational study cannot prove causality and are intended to generate hypotheses for future clinical trials on magnesium sulfate in term infants.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Minor KC, Liu J, Druzin ML, et al. Magnesium sulfate and risk of hypoxic-ischemic encephalopathy in a high-risk cohort. Am J Obstet Gynecol. 2024. PMID: 38580044. doi:10.1016/j.ajog.2024.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。